Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Cyclacel
Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules
May 02, 2024
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
April 30, 2024
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
April 01, 2024
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 19, 2024
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
March 13, 2024
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
March 07, 2024
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
March 06, 2024
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference
February 20, 2024
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer
January 30, 2024
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
January 08, 2024
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024
January 02, 2024
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules
December 22, 2023
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions
December 18, 2023
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals Announces Reverse Stock Split
December 12, 2023
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC
November 30, 2023
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q
November 28, 2023
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
November 13, 2023
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results
November 07, 2023
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
August 09, 2023
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results
August 03, 2023
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
May 11, 2023
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals to Release First Quarter 2023 Financial Results
May 04, 2023
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit
May 03, 2023
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals to Participate in March Investor Conferences
March 07, 2023
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Year 2022 Financial Results And Provides Business Update
March 06, 2023
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2022 Financial Results
February 27, 2023
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals to Participate in the 2023 BIO CEO & Investor Conference
January 30, 2023
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objectives for 2023
January 05, 2023
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals to Present at Biotech Showcase and Participate in a Corporate Access Event During the J.P. Morgan Healthcare Conference in January 2023
December 15, 2022
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
November 09, 2022
From
Cyclacel
Via
GlobeNewswire
Tickers
CYCC
CYCCP
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.